medigraphic.com
ISSN 1665-3254 (Print)
Revista Oficial de la Universidad Biomédica Rafael Guízar y Valencia A. C.

2021, Number 1

<< Back Next >>

Plasticidad y Restauración Neurológica 2021; 8 (1)

Vaccination against SARS-CoV-2: a global strategy to cope with the pandemic

Escobedo-de PJ

Language: Spanish
References: 37
Page: 13-18
PDF size: 193.31 Kb.


ABSTRACT

Objective: To present data regarding vaccination against COVID-19. Material and methods: Published information was reviewed regarding population studies assessing the effectiveness of COVID-19 vaccination in different populations. Results: Effectiveness of COVID-19 vaccine varies in diverse populations, mainly due to the platforms employed while developing the vaccines. Nevertheless, currently there is a broad spectrum of vaccine options, with adequate efficacy, safety, immunogenicity, and good effectiveness. Conclusions: Universal vaccination, together with the acquired immunity due to the disease, and non-pharmacological measures to prevent infection, like mask usage and social distancing, will help diminish the burden that this disease has posed to global health.


REFERENCES

  1. Escobedo-de la Peña J, Rascón Pacheco RA, Ascencio-Montiel IJ, González-Figueroa E, Fernández-Gárate JE, Medina-Gómez OS et al. Hypertension, diabetes and obesity, major risk factors for death in patients with COVID-19 in Mexico. Arch Med Res. 2021; 52 (4): 443-449. Available in: https://doi.org/10.1016/j.arcmed.2020.12.002

  2. Rabold E, Rovnan H, DuMont T. Isolation requirements and personal protective equipment in the COVID-19 pandemic. Crit Care Nurs Q. 2020; 43 (4): 407-412. Available in: https://doi.org/10.1097/CNQ.0000000000000326

  3. Excler JL, Saville M, Berkley S, Kim JH. Vaccine development for emerging infectious diseases. Nat Med. 2021; 27 (4): 591-600. Available in: https://doi.org/10.1038/s41591-021-01301-0

  4. Rossman H, Shilo S, Meir T, Gorfine M, Shalit U, Segal E. COVID-19 dynamics after a national immunization program in Israel. Nat Med. 2021; 27: 1055-1061. Available in: https://doi.org/10.1038/s41591-021-01337-2

  5. Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021; 397: 1819-1829. Available in: https://doi.org/10.1016/S0140-6736(21)00947-8

  6. Alagoz O, Sethi AK, Patterson BW, Churpek M, Alhanaee G, Scaria E, Safdar N. The impact of vaccination to control COVID-19 burden in the United States: a simulation modeling approach. medRxiv. 2021.03.22.21254131. Available in: https://doi.org/10.1101/2021.03.22.21254131

  7. Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA et al. BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021; 384: 1412-1423. Available in: https://doi.org/10.1056/NEJMoa2101765

  8. Chodick G, Tene L, Patalon T, Gazit S, Tov AB, Cohen D, Muhsen K. Assessment of effectiveness of 1 dose of BNT162b2 vaccine for SARS-CoV-2 infection 13 to 24 days after immunization. JAMA Network Open. 2021; 4 (6): e2115985. Available in: https://doi.org/10.1001/jamanetworkopen.2021.15985

  9. Jones NK, Rivett L, Seaman S, Samworth RJ, Warne B, Workman C et al. Single-dose BNT162b2 vaccine protects against asymptomatic SARS-CoV-2 infection. eLife. 2021; 10: e68808. Available in: https://doi.org/10.7554/eLife.68808

  10. Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A et al. Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021; 397: 1646-1657. Available in: https://doi.org/10.1016/S0140-6736(21)00677-2

  11. Lopez BJ, Andrews N, Gower C, Robertson C, Stowe J, Tessier E et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on COVID-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ. 2021; 373: n1088. Available in: http://dx.doi.org/10.1136/bmj.n1088

  12. Cook TM, Roberts JV. Impact of vaccination by priority group on UK deaths, hospital admissions and intensive care admissions from COVID-19. Anaesthesia. 2021; 76: 608-616. Available in: http://dx.doi.org/10.1111/anae.15442

  13. Butt AA, Omer SB, Yan P, Shaikh OS, Mayr FB. SARS-CoV-2 vaccine effectiveness in a high-risk national population in a real-world setting. Ann Intern Med [Internet]. 2021; [Epub ahead of print 20 July 2021]. Available in: http://dx.doi.org/doi:10.7326/M21-1577

  14. Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB et al. Decreases in COVID-19 cases, emergency department visits, hospital admissions, and deaths among older adults following the introduction of COVID-19 vaccine-United States, September 6, 2020-May 1, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 858-864. Available in: http://dx.doi.org/10.15585/mmwr.mm7023e2

  15. Pingali C, Meghani M, Razzaghi H, Lamias MJ, Weintraub E, Kenigsberg TA et al. COVID-19 vaccination coverage among insured persons aged ≥ 16 years, by race/ethnicity and other selected characteristics-eight integrated health care organizations, United States, December 14, 2020-May 15, 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 985-990. Available in: http://dx.doi.org/10.15585/mmwr.mm7028a1

  16. Lee JT, Althomsons SP, Wu H, Budnitz DS, Kalayil EJ, Lindley MC et al. Disparities in COVID-19 vaccination coverage among health care personnel working in long-term care facilities, by job category, National Healthcare Safety Network-United States, March 2021. MMWR Morb Mortal Wkly Rep. 2021; 70: 1036-1039. Available in: http://dx.doi.org/10.15585/mmwr.mm7030a2

  17. Jara A, Undurraga EA, González C, Paredes F, Fontecilla T, Jara G et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. New Engl J Med [Internet]. 2021; [Epub ahead of print 7 July 2021]. Available in: http://dx.doi.org/10.1056/NEJMoa2107715

  18. Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J et al. Prevention and attenuation of COVID-19 with the BNT162b2 and mRNA-1273 vaccines. N Engl J Med. 2021; 385: 320-329. Available in: http://dx.doi.org/10.1056/NEJMoa2107058

  19. Gohil SK, Olenslager K, Quan KA, Dastur CK, Afsar N, Chang W et al. Asymptomatic and symptomatic COVID-19 infections among health care personnel before and after vaccination. JAMA Network Open. 2021; 4 (7): e2115980. Available in: https://doi.org/10.1001/jamanetworkopen.2021.15980

  20. Azamgarhi T, Hodgkinson M, Shah A, Skinner JA, Hauptmannova I, Briggs TWR et al. BNT162b2 vaccine uptake and effectiveness in UK healthcare workers- a single centre cohort study. Nat Commun. 2021; 12: 3698. Available in: https://doi.org/10.1038/s41467-021-23927-x

  21. Hitchings MDT, Ranzani OT, Scaramuzzini TMS, Barbosa OS, Almiron M et al. Effectiveness of CoronaVac among healthcare workers in the setting of high SARS-CoV-2 gamma variant transmission in Manaus, Brazil: a test-negative case-control study. Lancet Reg Health-Americas. 2021:100025. Available in: https://doi.org/10.1016/j.lana.2021.100025

  22. Brown CM, Vostok J, Johnson H, Burns M, Gharpure R, Sami S et al. Outbreak of SARS-CoV-2 infections, including COVID-19 vaccine breakthrough infections, associated with large public gatherings-Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep. 2021; 70 (31): 1059-1062. Available in: http://dx.doi.org/10.15585/mmwr.mm7031e2

  23. Williams SV, Vusirikala A, Ladhani SN, Fernandez R, De Olano E, Iyanger N et al. . An outbreak caused by the SARS-CoV-2 Delta (B.1.617.2) variant in a care home after partial vaccination with a single dose of the COVID-19 vaccine Vaxzevria, London, England, April 2021. Euro Surveill. 2021; 26 (27): pii=2100626. Available in: https://doi.org/10.2807/1560-7917.ES.2021.26.27.2100626

  24. Charmet T, Schaeffer L, Grant R, Galmiche S, Chény O, Von Platen C et al. Impact of original, B.1.1.7, and B.1.351/P.1 SARS-CoV-2 lineages on vaccine effectiveness of two doses of COVID-19 mRNA vaccines: Results from a nationwide case-control study in France. Lancet Reg Health-Europe. 2021; 100171. Available in: https://doi.org/10.1016/j.lanepe.2021.100171

  25. Becker M, Dulovic A, Junker D, Ruetalo N, Kaiser PD, Pinilla YT et al. Immune response to SARS-CoV-2 variants of concern in vaccinated individuals. Nat Commun. 2021; 12: 3109. Available in: https://doi.org/10.1038/s41467-021-23473-6

  26. Jalkanen P, Kolehmainen P, Hakkinen HK, Huttunen M, Tahtinen PA, Lundberg R et al. COVID-19 mRNA vaccine induced antibody responses against three SARS-CoV-2 variants. Nat Commun. 2021; 12: 3991. Available in: https://doi.org/10.1038/s41467-021-24285-4

  27. Liu Y, Liu J, Xia H, Zhang X, Zou J, Fontes-Garfias CR et al. BNT162b2-elicited neutralization against new SARS-CoV-2 spike variants. N Engl J Med. 2021; 385: 472-474. Available in: https://doi.org/10.1056/NEJMc2106083

  28. Lopez BJ, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. New Engl J Med [Internet]. 2021; [Epub ahead of print 21 July 2021]. Available in: https://doi.org/10.1056/NEJMoa2108891

  29. Sheikh A, McMenamin J, Taylor B, Robertson C, on behalf of Public Health Scotland and the EAVE II Collaborators. SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness. Lancet. 2021; 397: 2461-2462. Available in: https://doi.org/10.1016/S0140-6736(21)01358-1

  30. Zitt E, Davidovic T, Schimpf J, Abbassi-Nik A, Mutschlechner B, Ulmer H et al. The safety and immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 vaccine in hemodialysis patients. Front Immunol. 2021; 12: 704773. Available in: https://doi.org/10.3389/fimmu.2021.704773

  31. Stumpf J, Siepmann T, Lindner T, Karger C, Schwobel J, Anders L et al. Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: a prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine. Lancet Reg Health – Europe 2021; [Epub ahead of print 23 July 2021]: 100178. Available in: https://doi.org/10.1016/j.lanepe.2021.100178

  32. Rabinowich L, Grupper A, Baruch R, Ben-Yehoyada M, Halperin T, Turner D et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. J Hepatol. 2021; 75: 435-438. Available in: https://doi.org/10.1016/j.jhep.2021.04.020

  33. Benotmane I, Gautier G, Perrin P, Olagne J, Cognard N, Fafi-Kremer S et al. Antibody response after a third dose of the mRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients with minimal serologic response to 2 doses. JAMA. 2021; Published online July 23, 2021. Available in: https://doi.org/10.1001/jama.2021.12339

  34. Kamar N, Abravanel F, Marion O, Couat C, Izopet J, Del Bello A. Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients. N Engl J Med [Internet]. 2021; [Epub ahead of print 23 June 2021]. Available in: https://doi.org/10.1056/NEJMc2108861

  35. Monin L, Laing AG, Muñoz-Ruiz M, McKenzie DR, del Molino del Barrio I, Alaguthurai T et al. Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study. Lancet Oncol. 2021; 22: 765-778. Available in: https://doi.org/10.1016/S1470-2045(21)00213-8

  36. Medeiros-Ribeiro AC, Aikawa NE, Saad CGS. et al. Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial. Nat Med [Internert] 2021; [Epub ahead of print 30 Jul 2021]. Available in: https://doi.org/10.1038/s41591-021-01469-5

  37. Shimabukuro TT, Kim SY, Myers TR, Moro PL, Oduyebo T, Panagiotakopoulos L et al. Preliminary findings of mRNA Covid-19 vaccine safety in pregnant persons. N Engl J Med. 2021; 384: 2273-2282. Available in: https://doi.org/10.1056/NEJMoa2104983




2020     |     www.medigraphic.com